Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Juluca

- PMLiVE

Galapagos mid-stage trial failure raises concerns for Gilead deal

Investigational osteoarthritis treatment misses primary endpoint in phase 2 study

- PMLiVE

WHO trial casts doubt on remdesivir’s efficacy

Drug's developer Gilead hits back at the findings

- PMLiVE

EU announces agreement with Gilead for remdesivir supply

Drug was granted conditional marketing authorisation in the EU in July

- PMLiVE

Gilead agrees $21bn buyout of Immunomedics

Pharma company gains rights to ADC Trodelvy

- PMLiVE

Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

The combination treatment hit the primary study endpoint of a reduction in recovery time

- PMLiVE

Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Disruption to uptake of HIV and hepatitis C drugs caused by pandemic

- PMLiVE

Gilead makes a play for novel cancer drug with Tizona deal

Pharma company continues oncology biotech spending spree

- PMLiVE

Gilead and Arcus complete closing of ten-year immunotherapy partnership

Deal emphasises Gilead's focus on immuno-oncology

- PMLiVE

Gilead reports remdesivir cuts risk of death in severe COVID-19 patients

Also reveals new analyses from compassionate use programme

- PMLiVE

UPDATED: Gilead drops remdesivir’s orphan drug designation

Decision comes amid intense public criticism of the regulatory status

- PMLiVE

Gilead halts individual requests for COVID-19 hopeful remdesivir

Will now focus on expanded access programmes and backlog

- PMLiVE

NHS England will make PrEP for HIV available in April

Will be made available to patients at risk of contracting infection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links